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48* Nebulized SLIT™ Amikacin in the treatment of cystic ﬁbrosis
patients with chronic Pseudomonas aeruginosa lung infection in
Serbia and Hungary
C. Mackinson1, P. Minic2, A. Sovtic2, A. Forrest3, R. Gupta1. 1Transave, Inc,
Monmouth Junction, NJ, USA; 2Pulmonology and Bronchology, Mother and
Child Health Institute of Serbia, Belgrade, Yugoslavia; 3Institute for Clinical
Pharmacodynamics, Albany, NY, USA
SLIT™ Amikacin is a sustained-release lipid formulation of amikacin for inhalation,
being developed for the treatment of P. aeruginosa (Pa) infections in CF patients.
A Phase Ia/IIb clinical study was conducted with a total of 13 patients treated
for 14 days with 500mg qd SLIT Amikacin by nebulization. Patients were naı¨ve
to inhaled antibiotics. Pseudomonas isolates at screening had amikacin minimum
inhibitory concentration (MIC) values of 16 ug/mL. The drug was safe and well
tolerated with no nephrotoxicity to date. Systemic exposure to SLIT Amikacin was
very low. Final data analysis showed clinically relevant improvement in FEV1 and a
decreased bacterial density. The absolute change (mean) in FEV-1 liters at days 14
(post last dose), 28 and 42 (28 day follow-up) were 0.26, 0.24 and 0.31. There
appeared to be a trend for decreased CFUs that correlated with improvements
in FEV-1. The results demonstrate once a day treatment with nebulized SLIT
Amikacin is safe and elicits a clinically relevant effect on pulmonary function
and Pa density of CF patients.
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Only in a half of patient with cystic ﬁbrosis (CF) a systemic ﬂavonoid therapy
showed a clinical improvement [1]. In about 30% of CF-patients the chloride trans-
port over CFTR-dependent chloride channels increased under ﬂavonoid therapy [2].
Suggesting an insufﬁcient resorption of ﬂavonoids in that CF-patients without
positive effects, the aim was to ﬁnd out a measurement of ﬂavonoids in blood
of patients.
Recently it was possible for the ﬁrst time to detect quercetin, an important
member of ﬂavonoids, in blood samples by a combination of high pressure liquid
chromatography (HPLC) with mass spectrometry.
Quercetin, quercetin-glycoside, -glucoronide, and sulphate were transformed by acid
hydrolysis.
The determinations are performed by HPLC and after a derivativity with aluminum
nitrate.
In 35 CF-patients (3−65 y.) measurements were performed. In 21 patients (3−24 y.)
without ﬂavonoids the values amounted to 560 ng/ml (350–827 ng/ml), in CF-
patients with ﬂavonoid-therapy quercetin-plasma-levels the values amount to
1147 ng/ml (±759 ng/ml). In some patients the values are under 500 ng/ml, in spite
of ﬂavonoid therapy.
Flavonoids are detectable in blood-samples by a combination of an high pres-
sure liquid chromatography (HPLC) with mass spectrometry. Under an additional
ﬂavonoid-therapy the blood-level increased. In patients with low levels of quercetin
in spite of ﬂavonoid-therapy the intestinal absorption must be disturbed.
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50 Pharmacokinetic comparison of inhaled tobramycin (TOBI®) via PARI
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This study compared the pharmacokinetics & safety of tobramycin solution for
inhalation (TOBI®) delivered via the PARI eFlow® rapid nebulizer vs the PARI LC
Plus™ jet nebulizer. TOBI 300mg was administered bid for 2 wks in a randomized,
crossover study in 25 cystic ﬁbrosis patients aged 19−44 yrs.
Methods: Blood & sputum samples were collected on days 1 & 15 at 0, 0.5, 1, 1.5, 2, 4,
8 h & 0, 0.5, 1.5, 2, 8 h, respectively. Drug serum levels were analyzed by ﬂuorescence
polarization immunoassay & sputum samples by HPLC.
Results: Mean total nebulization time was halved with eFlow rapid (7.4 min) vs LC
Plus (17.2 min) & mean systemic exposure was slightly lower vs LC Plus at day 15
(table). Although highly variable between subjects, mean sputum levels were on average
2-fold higher with eFlow rapid than LC Plus. Adverse events (AEs), all mild–moderate,
were reported by 16 patients using LC Plus (mainly headache, abdominal pain) vs
19 patients on eFlow rapid (mainly headache, cough, dyspnea) with no premature
discontinuations due to AEs. No clinically signiﬁcant bronchospasm (20% decrease
in FEV1) occurred. Mean changes in FEV1 from predose to 30 min post-dose on day
15 were −2.76% (LC Plus) vs −1.27% (eFlow rapid).
Parameter LC Plus™ nebulizer eFlow® rapid nebulizer
Predose (ug/ml) 0.11±0.08 0.15±0.15
Cmax (ug/ml) 1.32±0.68 1.22±0.96
AUC (ug.h/ml) 5.10±2.56 4.83±3.55
Conclusions: TOBI delivered via the eFlow rapid nebulizer, compared with the LC
Plus jet nebulizer, reduced delivery time by 50%, reduced systemic drug exposure,
produced higher mean tobramycin sputum levels & maintained a similar safety proﬁle.
Supported by: Novartis Pharma AG.
51 Lung deposition and pharmacokinetics in 12 lung transplanted
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Objectives: To investigate lung deposition and pharmacokinetics in 12 adult lung
transplanted patients upon inhalation of 10mg/2ml and 20mg/4ml liposomal CsA
by the eFlow electronic nebuliser, both developed by PARI Pharma.
Methods: At two visits 10mg/2 ml and 20mg/4 ml of a radiolabeled liposomal
CsA formulation, each, were inhaled by 7 single (SLTx) and 5 double side (DTLx)
transplanted adult patients (mean age 58 yrs) via a customised eFlow 30L electronic
nebuliser. Lung images were recorded immediately after inhalation by a gamma
camera. In addition, blood samples were taken after 2, 4, 6, 8, and 24 h, and CsA
was quantiﬁed by a validated HPLC-MS/MS method.
Results: Inhalation of the liposomal CsA formulation was well tolerated without any
pre-medication by all patients. Mean deposition for the lower dose was 4.0±0.6mg
and for the higher dose 6.5±1.4mg. in each case, about 50% of the lung dose was
found in the periphery of the lungs. About 90% of the lung dose in SLTx patients
was found in the transplanted lung corresponding to 3.5±0.6 and 5.8±1.4mg for
the low and high dose, respectively. AUC was 110 and 190 h ng/ml, Cmax = 20 and
31 ng/ml and t1/2 = 5.2 and 6.1 h for the 10 and 20mg dose, respectively.
Conclusions: A correlation was found for total and peripheral lung deposition with
the treatment time. The pharmacokinetic parameters AUC and Cmax correlate with
peripheral lung deposition. SLTx patients require only about half the loaded dose
into the nebuliser, since 90% of the drug is found in the transplanted lung.
